Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 06, 2026
TickeronGET DAILY SIGNALS
Revolution Beauty (REVB) Marks Turnaround Milestone with Positive Adjusted EBITDA

Revolution Beauty (REVB) Marks Turnaround Milestone with Positive Adjusted EBITDA

Key Takeaways

  • Revolution Beauty swung to a positive adjusted EBITDA of £2.0 million in the first half of fiscal 2027, versus a £12.5 million loss a year earlier.
  • Headline revenue slipped 2% to £48.4 million, but underlying revenue rose 8.3% after stripping out prior-year clearance sales, discontinued brands, and one-off license income.
  • Gross margin climbed to 43.6% from 32.2%, while the loss before tax narrowed sharply to £1.9 million from £18.4 million.
  • Online sales grew 22%, led by TikTok Shop, alongside the company's own website and Amazon channels.
  • Management expects full-year results at the top end of market forecasts — revenue of £92.0 million to £95.0 million and adjusted EBITDA of £6.0 million to £6.6 million.
  • The interim results also disclosed a material uncertainty over going concern, a reminder that the recovery remains dependent on cost savings and working capital improvements.

Understanding the Earnings Context

Revolution Beauty Group, the mass beauty and personal care business behind brands such as REVOLUTION and Makeup Revolution, has spent recent years working through a difficult restructuring. The company returned its co-founders to leadership, cut costs, and exited non-core brands and products after a period of heavy losses. Its fiscal year runs from March to February, making the six months ended 31 August 2026 the first half of fiscal 2027. Because this interim report marks the first half-year period in which the group generated positive adjusted EBITDA, it serves as an important checkpoint on whether the turnaround is genuinely translating into sustainable profitability rather than simply narrower losses.

Breaking Down the Reported Results

For the six months ended 31 August 2026, Revolution Beauty reported adjusted EBITDA of £2.0 million, a swing from the £12.5 million loss recorded in the same period a year earlier. Revenue came in at £48.4 million, down about 2% on a headline basis, reflecting the removal of discontinued brands, prior-year clearance activity, and one-off license income. Excluding those items, underlying revenue grew 8.3%.

Gross margin improved materially to 43.6% from 32.2%, helped by the absence of clearance sales, lower gross-to-net charges, and tighter inventory and range management. Operating costs fell roughly 33% to £19.1 million, and the loss before tax narrowed to £1.9 million from £18.4 million. Reported loss per share was GBX 0.20.

Online sales across the company's own website, TikTok Shop, and Amazon rose 22%, driven primarily by TikTok Shop. Net debt declined to £25.7 million from £30.2 million a year earlier, with cash of £4.3 million. Management said September and October trading was in line with expectations and guided toward the top end of full-year market forecasts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Investor Response and Sentiment

Investor reaction to the interim results was mixed. The shares had rallied strongly in the run-up to the announcement, and the market's focus remained on forward momentum rather than the historical figures. The confirmation of a return to positive adjusted EBITDA, a sharp gross margin improvement, and online sales growth were seen as evidence that the turnaround is progressing. However, the disclosure of a material uncertainty over going concern tempered enthusiasm, highlighting that the group could breach financing covenants in a severe downside scenario unless further mitigating actions succeed. This balance between improving operational trends and lingering balance-sheet risk has kept sentiment cautious even as management described trading as comfortably ahead of expectations.

Looking Ahead: Outlook and Monitoring Points

Management enters the seasonally stronger second half with several growth levers in motion. The company's licensing partnership with Debenhams Group — covering fragrance and gifting under the PrettyLittleThing, Karen Millen, and boohooMAN brands — is expected to launch its first collections ahead of Christmas. Retailer order books are showing early signs of a positive response to range changes, and online channels remain a forward indicator of demand.

Investors will be watching whether gross margin holds in the low-to-mid 40% range, whether the 22% online growth led by TikTok Shop proves sustainable, and whether US and international revenue stabilize after recent declines. The festive trading period represents the next major test of demand.

Balance-sheet resilience remains a central theme. Net debt has fallen, but the going-concern uncertainty means covenant headroom, working capital management, and the outcome of ongoing commercial matters and claims will be closely monitored. The company expects full-year revenue of £92.0 million to £95.0 million and adjusted EBITDA of £6.0 million to £6.6 million, positioning the second half as the decisive period for confirming a durable return to profitable growth. From what I see, ongoing monitoring of these factors will be key for REVB.

Enhancing Analysis with AI Tools

In my own research, I find Tickeron’s AI Screener particularly useful for quickly identifying comparable turnaround candidates across consumer sectors. It streamlines the process of filtering by fundamentals and trends, helping me cross-check ideas like this one without spending hours on manual screens.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: REVB

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


REVB in upward trend: price may jump up because it broke its lower Bollinger Band on October 16, 2026

REVB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 46 of 53 cases where REVB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where REVB's RSI Oscillator exited the oversold zone, 38 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for REVB just turned positive on October 30, 2026. Looking at past instances where REVB's MACD turned positive, the stock continued to rise in 32 of 38 cases over the following month. The odds of a continued upward trend are 84%.

Following a +12.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where REVB advanced for three days, in 144 of 179 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 29 cases where REVB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REVB as a result. In 76 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REVB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for REVB entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.535) is normal, around the industry mean (2.788). P/E Ratio (0.144) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. REVB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.16B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 8%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -15%. LABT experienced the highest price growth at 128%, while KPTI experienced the biggest fall at -93%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 99%. For the same stocks of the Industry, the average monthly volume growth was 66% and the average quarterly volume growth was 5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
4660 La Jolla Village Drive
Phone
+1 650 800-3717
Employees
9
Web
https://www.revbiosciences.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
PANW stock rose approximately +11% over the past 30 days, driven by recovery in cybersecurity sentiment and strong enterprise wins. Over the past quarter, shares gained +3% amid volatility, reflecting a post-earnings dip followed by steady rebound.
Altria Group (MO) stock rose approximately +13% over the past 30 days, driven primarily by a strong Q1 2026 earnings beat that propelled shares sharply higher at month-end. Over the past quarter, shares gained around +16%, reflecting recovery from earlier lows amid consistent operational performance and a shift toward smokefree products.
Revolution Beauty (REVB) Marks Turnaround Milestone with Positive Adjusted EBITDA